The combined activation of the inflammasome pathway, which leads to substantial MDSC recruitment, and CD38 activation, which reduces the sensitivity of tumor cells to IFN-γ through ADORA2a activation, may lead to a loss of therapeutic efficacy and uncontrolled tumor progression. The gene discussed is ADORA2A; the disease is neoplasm.